KH617

DRUG2 trials

Sponsors

Sichuan Honghe Biotechnology Co., Ltd.

Conditions

Advanced Solid TumorsRecurrent Glioblastoma

Phase 1

Phase 1 Trial of KH617

RecruitingNCT05667194

Sichuan Honghe Biotechnology Co., Ltd.Advanced Solid Tumors

Start: 2022-12-26End: 2031-08-31Target: 45Updated: 2024-11-27

Phase 2

Phase 2 Clinical Trial of KH617

Not yet recruitingNCT07138001

Sichuan Honghe Biotechnology Co., Ltd.Recurrent Glioblastoma

Start: 2025-08-31End: 2030-12-31Target: 60Updated: 2025-08-22

Related Papers

Abstract LB035: The natural compound KH617: A safe and selective therapeutic agent targeting GBM metabolic reprogramming

Cancer Research2026-04-17

Abstract LB034: Broad-spectrum antitumor activity of the biosynthetically derived molecule KHN705

Cancer Research2026-04-17

Abstract LB032: The natural compound KH617 reverses glioblastoma resistance to alkylating agents via MGMT modulation

Cancer Research2026-04-17